Third Quarter 2024 Results Key Financial Results Net loss: US$76.7m (loss ...

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) on November 12 and set a ...

On Friday, Viridian Therapeutics Inc (VRDN) stock saw a decline, ending the day at $20.14 which represents a decrease of $-1.50 or -6.93% from the prior close of $21.64. The stock opened at $21.72 and ...

Not for distribution to U.S. news wire services or for dissemination in the United States VANCOUVER, British Columbia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- (TSXV:VRDN) (the “Company”) formerly Coco Pool ...

November 12, 2024--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.

Viridian Therapeutics ( (VRDN)) has issued an update. Viridian Therapeutics, a biotech company, highlights its recent advancements in treating thyroid eye disease (TED) and FcRn inhibitor ...

Colonial First State has announced an arrangement with Viridian Advisory to allow CFS FirstChoice superannuation, pension and investment members who do not have a financial adviser to access one-off, ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering ...

Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED.

Colonial First State has signed a deal with advice house Viridian Advisory to give its members access to low-cost personal ...